Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aRSubstantial progress made toward Phase 2b ...
PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
Indaptus Therapeutics, Inc. announced its progress in 2024 and goals for 2025, focusing on its lead candidate, Decoy20, an innovative immunotherapy for cancer and viral infections. The company ...
Virginia Beach leaders convened Wednesday to reflect on the city’s progress over the past year, tackle ongoing challenges and ...
2025 milestones reinforce EagleNXT’s growing role in global aerial intelligence markets and establish a strong foundation for scale in 2026 WICHITA, Kan., Dec. 16, 2025 (GLOBE NEWSWIRE) -- AgEagle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results